1 / 31

Chapter 16 Drugs Affecting Muscle Spasm and Spasticity

Chapter 16 Drugs Affecting Muscle Spasm and Spasticity. Physiology . The human body contains approximately 600 skeletal muscles. Skeletal muscle movement is voluntary. Striated muscle is composed of two contractile proteins.

Mercy
Download Presentation

Chapter 16 Drugs Affecting Muscle Spasm and Spasticity

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Chapter 16Drugs Affecting Muscle Spasm and Spasticity

  2. Physiology • The human body contains approximately 600 skeletal muscles. • Skeletal muscle movement is voluntary. • Striated muscle is composed of two contractile proteins. • Muscle contraction is triggered by a sudden inflow of calcium ions (Ca2+). • In the resting state, the protein tropomyosin winds around actin and covers the myosin-binding sites. • Muscle contraction stops when Ca2+ is removed from the immediate environment of the myofilaments.

  3. Muscle Fibers <Insert Figure 16.1>

  4. Pathophysiology • Muscle spasm • A muscle spasm is a sudden, violent involuntary contraction of a muscle or group of muscles. • Spasms are related to a localized skeletal muscle injury or an imbalance in electrolytes. • Tonic spasm is characterized by an unusually prolonged and strong muscular contraction • Spasticity • Spasticity is a condition in which certain muscles are continuously contracted. • This contraction causes stiffness or tightness of the muscles. • Spasticity may be associated with spinal cord injury.

  5. Centrally Acting Muscle Relaxants • They act in the central nervous system (CNS). • Prototype drug: cyclobenzaprine (Flexeril)

  6. Cyclobenzaprine: Core Drug Knowledge • Pharmacotherapeutics • Manages muscle spasms associated with acute musculoskeletal disorders • Pharmacokinetics • Administered: oral. Metabolism: liver. Excreted: urine and bile. Onset: 1 hour. Duration: 12-24 hours. • Pharmacodynamics • Relieves muscle spasms through a central action

  7. Cyclobenzaprine: Core Drug Knowledge(cont.) • Contraindications and precautions • Hyperthyroidism • 14 days within use of MAOIs • Adverse effects • CNS depression and anticholinergic activity • Arrhythmias, seizures, and MIs • Drug interactions • Tramadol, guanethidine, MAOIs, histamine-1 blocking agents, and various herbal remedies

  8. Cyclobenzaprine: Core Patient Variables • Health status • Assess past medical history and drug allergies • Life span and gender • Pregnancy category B • Use precaution in administration to elderly • Lifestyle, diet, and habits • Avoid alcohol and other CNS depressant use • Environment • Assess environment where drug will be given

  9. Cyclobenzaprine: Nursing Diagnoses and Outcomes • Risk for Injury related to CNS depressant effects and potential cardiovascular effects. • Desired outcome: the patient will remain free from injury throughout therapy.

  10. Cyclobenzaprine: Planning and Interventions • Maximizing therapeutic effects • Take with full glass of water at evenly spaced intervals • Coordinate physical therapies with administration • Minimizing adverse effects • Assess for excessive sedation • Caution the patient about the potential for orthostatic hypotension

  11. Cyclobenzaprine: Teaching, Assessment & Evaluation • Patient and family education • Take medication as prescribed • Explain adverse effects • Do not take with other OTC medications • Ongoing assessment and evaluation • Evaluate patient’s safety • Monitor level of sedation

  12. Question Cyclobenzaprine is chemically similar to what drug? A. Adrenergic agents B. Benzodiazepines C. Tricyclic antidepressants D. MAOIs

  13. Rationale Cyclobenzaprine is chemically similar to what drug? C. Tricyclic antidepressants Cyclobenzaprine is structurally similar to the tricyclic antidepressants.

  14. Centrally Acting Spasmolytics • The centrally acting spasmolytics work in the CNS to reduce excessive reflex activity • Allow muscle relaxation • Prototype drug: baclofen (Lioresal)

  15. Baclofen: Core Drug Knowledge • Pharmacotherapeutics • Relieves some components of spinal spasticity • Pharmacokinetics • Administered: oral. Distribution: crosses blood–brain barrier. Metabolism: liver. Excreted: urine and bile. Peaks: 2–3 hours. • Pharmacodynamics • Acts specifically at the spinal end of the upper motor neurons at GABAB receptors to cause hyperpolarization

  16. Baclofen: Core Drug Knowledge • Contraindications and precautions • Hypersensitivity and spasticity of cerebral origin • Adverse effects • Drowsiness, weakness, dizziness and lightheadedness, headache, nausea and vomiting, hypotension, constipation, lethargy and fatigue, confusion, insomnia, and increased urinary frequency • Drug interactions • CNS depressants or TCAs

  17. Baclofen: Core Patient Variables • Health status • Assess past medical history and allergies • Peform physical assessment • Life span and gender • Older patients are more susceptible to sedation • Lifestyle, diet, and habits • Caution the patient about the concurrent use of alcohol • Environment • Assess environment where drug will be given. It isusually given at the home.

  18. Baclofen: Nursing Diagnoses and Outcomes • Acute Pain related to headache, muscle pain, GI disturbances, or rash • Desired outcome: the patient will be provided with measures to decrease the discomfort of drug therapy and the possibility of nonadherence. • Risk for Disturbed Sensory Perception related to visual changes, vestibular dysfunction, and somatosensory changes • Desired outcome: the patient will be protected from injury if dizziness, weakness, visual changes, or perceptual changes occur.

  19. Baclofen: Planning and Interventions • Maximizing therapeutic effects • Take with full glass of water at evenly spaced intervals • If GI distress occurs, coordinate with meals • Minimizing adverse effects • Ensure patient safety • Do not abruptly stop medication

  20. Baclofen: Teaching, Assessment & Evaluation • Patient and family education • Teach importance of patient safety • Caution the patient about the concurrent use of alcohol • Ongoing assessment and evaluation • Monitor for the emergence of hallucinations or psychotic episodes • Assess for improved symptoms of spasticity

  21. Question • Baclofen therapy is effective at treating muscle spasms due to a cerebral vascular accident. • A. True • B. False

  22. Rationale • Baclofen therapy is effective at treating muscle spasms due to a cerebral vascular accident. • B. False • Baclofen therapy does not affect skeletal muscle spasms resulting from CVA or parkinsonism. Baclofen does not treat this condition because of the mechanism of action of the drug.

  23. Peripherally Acting Spasmolytics • Peripherally acting spasmolytics relax muscles through direct action on the skeletal muscle fibers. • They do not interfere with neuromuscular communication. • They have no CNS effects. • Prototype drug: dantrolene (Dantrium).

  24. Dantrolene: Core Drug Knowledge • Pharmacotherapeutics • Used to treat malignant hyperthermia • Pharmacokinetics • Administered: oral or IV. Metabolism: liver. Excreted: kidneys. Peak: 5 hours. T½: 7.3 hours. • Pharmacodynamics • Reduces the amount of Ca2+ released from the sarcoplasmic reticulum, thereby relaxing the muscle

  25. Dantrolene: Core Drug Knowledge (cont.) • Contraindications and precautions • Liver disease • Adverse effects • Muscle weakness, fatal hepatitis, seizures, and pleural effusion with pericarditis • Drug interactions • CNS depressants, clofibrate, estrogens, verapamil, and warfarin.

  26. Dantrolene: Core Patient Variables • Health status • Assess past medical and physical assessment • Life span and gender • Consider the age before administration • Lifestyle, diet, and habits • Assess for lactose intolerance • Environment • Can cause photosensitivity

  27. Dantrolene: Nursing Diagnoses and Outcomes • Risk for Injury related to muscular weakness • Desired outcome: the patient will be injury free despite muscular weakness. • Risk for Disturbed Sensory Perception: Kinesthetic related to dizziness, malaise, and fatigue • Desired outcome: the patient will remain free of injury from adverse effects. • Disturbed Body Image related to drug-related dermatologic effects • Desired outcome: any adverse effects will be resolved by the end of therapy.

  28. Dantrolene: Planning and Interventions • Maximizing therapeutic effects • Administer with food or milk to avoid gastric distress • Do not crush extended release capsule • Minimizing adverse effects • Provide for patient safety • Advise the use of sunscreen • Titrate dose to maximum effectiveness

  29. Dantrolene: Teaching, Assessment, and Evaluation • Patient and family education • Explain why the drug is prescribed • Discuss adverse effects of drug • Ongoing assessment and evaluation • Monitor for improvement in symptoms of spasticity and decrease in resistance to passive movement • Monitor for adverse effects

  30. Question • Dantrolene is used to treat what condition(s)? • A. Hypertensive crisis • B. Malignant hyperthermia • C. Pain associated with lumbar stenosis • D. All of the above

  31. Rationale • Dantrolene is used to treat what condition(s)? • B. Malignant hyperthermia • IV dantrolene is the drug of choice for acute treatment of malignant hyperthermia. Preoperatively, it can be used orally or intravenously to prevent malignant hyperthermia in patients considered at risk.

More Related